Product Reports Resources Pricing Login Book a demo

Biocartis

Biotech & Life Sciences · Mechelen, Belgium · Founded 2007 · IPO 2015

Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments MoreLess

Biocartis is a pioneering molecular diagnostics company dedicated to transforming molecular testing through its unique IdyllaTM platform. The company provides advanced diagnostic solutions designed to improve clinical practice for patients, clinicians, payers, and the broader healthcare industry. Biocartis operates in the molecular diagnostics market, focusing on oncology and infectious diseases. Its primary clients include hospitals, laboratories, and healthcare providers who require rapid and accurate diagnostic results. The business model revolves around the sale of diagnostic instruments and consumables, generating revenue through the continuous use of its proprietary platform and assays. Biocartis makes money by selling its IdyllaTM platform and associated diagnostic tests, which offer quick and reliable results, thereby enhancing patient care and operational efficiency in clinical settings.

Keywords: molecular diagnostics, Idylla platform, oncology, infectious diseases, clinical practice, healthcare providers, rapid testing, diagnostic solutions, proprietary technology, patient care.

Valuation $170M
Revenue $52M
Total funding $100–500M

Talent graph

Biocartis's talent

Book a demo to see the people
Employees mapped 311 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

12 investors on Biocartis's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen
Series A 5 investors entered at this stage
Aescap
Advent Venture Partners
Johnson & Johnson Development Corporation
KBC
Debiopharm Group
Series B+ 6 investors entered at this stage
Wellcome Trust
PMV
Korys
RMM
Philips
Hitachi Chemical Diagnostics

Global footprint

Where Biocartis has talent and traffic

Workforce by country
19 countries with
team presence
🇧🇪 Belgium70.5%
🇺🇸 United States13.3%
🇩🇪 Germany2.9%
🇮🇹 Italy2.5%
🇫🇷 France2.5%
Top 5 of 19 shown
Web traffic by country
9.1K monthly visits
across markets
🇹🇼 Taiwan28.6%
🇧🇪 Belgium23.1%
🇺🇸 United States22%
🇪🇸 Spain17.6%
🇵🇱 Poland4.4%
Top 5 markets shown

Market sentiment

What the market is saying about Biocartis

An AI-synthesized read of the highest-engagement posts about Biocartis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biocartis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.